Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

ACC 2021: Key Studies Impacting Clinical Care of Heart Failure

Lee R. Goldberg, MD, MPH, FACC

Professor of Medicine
Division of Cardiovascular Medicine
Department of Medicine
Section Chief, Advanced Heart Failure and Cardia Transplant
Division of Cardiovascular Medicine
University of Pennsylvania
Philadelphia, Pennsylvania


Lee R. Goldberg, MD, MPH, FACC, has disclosed that he has performed contracted research for Respircardia, and received consulting fees from Abbott and Viscardia.


View ClinicalThoughts from this Author

Released: July 15, 2021

Several new interventions that will impact the care of patients with heart failure (HF) were presented at the 2021 American College of Cardiology (ACC) Annual Meeting.

Cardiovascular Protective Efficacy of the SGLT2 Inhibitor Empagliflozin in Asia
Over the past few years, the role of sodium-glucose cotransporter 2 (SGLT2) inhibitors has expanded from glucose lowering to a role in the prevention of cardiovascular disease, so it is critical that we understand how these drugs perform in different patient populations. In the EMPRISE study, Kim and colleagues evaluated the population effects of the use of empagliflozin by analyzing data from 3 large administrative databases from Japan, South Korea, and Taiwan. The study included 28,712 matched pairs of adult patients with type 2 diabetes initiating either empagliflozin or a dipeptidyl peptidase-4 inhibitor. Propensity score matched analyses comparing the risk of cardiovascular outcomes with all-cause mortality were computed. Subgroup analyses were performed in patients with and without preexisting cardiovascular disease who received 10 mg of empagliflozin. Empagliflozin was associated with a lower risk of the composite outcome of hospitalization for HF and all-cause mortality. A lower risk of the combined outcome of myocardial infarction, stroke, and all-cause mortality also was found in the empagliflozin group. These results are important, as they validate the use of SGLT2 inhibitors and—in particular—empagliflozin in people of East Asian descent and add to the evidence of the cardiovascular protective efficacy of this class of drugs.

Oral sGC Stimulators: Safety and Efficacy
Oral soluble guanylate cyclase (sGC) stimulators are the newest class of drugs to be approved in the treatment of HF. This class of drugs works by increasing cyclic guanosine monophosphate, leading to peripheral vasodilatation and a decrease in inflammation. Moghaddam and colleagues presented a meta-analysis of clinical trials evaluating sGC stimulators in patients with HF. Identified studies included 5707 patients with HF with reduced ejection fraction (HFrEF) and 1483 patients with HF with preserved ejection fraction (HFpEF). They found that the drugs were well tolerated and reduced HF hospitalizations, but not cardiovascular deaths, only in those with HFrEF. There were no benefits in patients with HFpEF. This class of drugs is being incorporated into the guidelines, so it will be important to introduce those medications with both symptomatic and mortality benefits first and then add those with only symptomatic benefit further in the algorithm.

Icosapent Ethyl: Preventive Benefit on the Incidence of New HF and New HF Requiring Hospitalization
In the area of prevention of HF, Bhatt and colleagues presented tertiary endpoints of the REDUCE-IT trial. The impact of icosapent ethyl was evaluated in patients with controlled low-density lipoprotein cholesterol but elevated triglycerides on the incidence of new HF (N = 8179). This double-blind, placebo-controlled phase III trial found no difference between icosapent ethyl and placebo in the incidence of new HF. However, post-hoc analysis showed that patients with the middle and highest tertile of on-treatment eicosapentaenoic acid had a significant benefit in terms of new HF and new HF requiring hospitalization. The implication is that it may be important to achieve a specific eicosapentaenoic acid target level to get the preventive benefit. This study further emphasizes that HF is a preventable disease with aggressive comprehensive risk factor reduction.

Cardiac Rehabilitation for Patients With HFpEF
Finally, a small, important study on the impact of cardiac rehabilitation for patients with HFpEF was presented by Ayad and colleagues. In this study, 60 patients with HFpEF were randomized to receive 2-3 cardiac rehabilitation sessions weekly or usual care only. After 12 weeks, patients on cardiac rehabilitation showed improvements in Minnesota Living with Heart Failure Questionnaire score, echocardiographic parameters, and 6-minute walk distance. This observation is critical in changing policy and driving additional research to expand access to cardiac rehabilitation for patients with HFpEF.

Your Thoughts?
Which new data from ACC will impact your clinical practice? Answer the polling question and join the conversation by posting in the discussion section. For more detail on these and other studies from ACC 2021, download capsule summaries of all the key data.

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Merck

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue